Cleared Traditional

K902636 - LIPOGEN RHEUMELISA DSDNA ASSAY

K902636 is an FDA 510(k) clearance for LIPOGEN RHEUMELISA DSDNA ASSAY, manufactured by Lipogen, Inc.. The device is a Class 1 Immunology device with product code LRY cleared through the Traditional 510(k) pathway after a 14-day FDA review.

K902636 · Lipogen, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 1990
Decision
14d
Days
Class 1
Risk

K902636 is an FDA 510(k) clearance for the LIPOGEN RHEUMELISA DSDNA ASSAY. Classified as Punch, Surgical (product code LRY), Class I - General Controls.

Submitted by Lipogen, Inc. (Knoxville, US). The FDA issued a Cleared decision on June 28, 1990 after a review of 14 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 878.4800 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Lipogen, Inc. devices

FDA 510(k) Submission Details - K902636

510(k) Number K902636 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 14, 1990
Decision Date June 28, 1990
Days to Decision 14 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
91d faster than avg
Panel avg: 105d · This submission: 14d
Pathway characteristics
Predicate-based equivalence.

LRY Device Classification - Class 1, General Controls

Product Code LRY Punch, Surgical
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 878.4800
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.